Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Drunk Without Drinking: A Case of Auto-Brewery Syndrome.

Akhavan BJ, Ostrosky-Zeichner L, Thomas EJ.

ACG Case Rep J. 2019 Sep 9;6(9):e00208. doi: 10.14309/crj.0000000000000208. eCollection 2019 Sep.

2.

Simultaneous Infection with Enterobacteriaceae and Pseudomonas aeruginosa harboring Multiple Carbapenemases in a Returning Traveler colonized with Candida auris.

Khan A, Shropshire WC, Hanson B, Dinh AQ, Wanger A, Ostrosky-Zeichner L, Arias CA, Miller WR.

Antimicrob Agents Chemother. 2019 Oct 28. pii: AAC.01466-19. doi: 10.1128/AAC.01466-19. [Epub ahead of print]

PMID:
31658962
3.

Candida auris: what have we learned so far?

Corsi-Vasquez G, Ostrosky-Zeichner L.

Curr Opin Infect Dis. 2019 Dec;32(6):559-564. doi: 10.1097/QCO.0000000000000603.

PMID:
31592823
4.

Point-Counterpoint: Should serum β-D- glucan testing be used for the diagnosis of Pneumocystis jiroveci pneumonia?

Corsi-Vasquez G, Ostrosky-Zeichner L, Pilkington EF 3rd, Sax PE.

J Clin Microbiol. 2019 Aug 21. pii: JCM.01340-19. doi: 10.1128/JCM.01340-19. [Epub ahead of print]

PMID:
31434728
5.

Seroprevalence of Strongyloides stercoralis and Evaluation of Universal Screening in Kidney Transplant Candidates: A Single-Center Experience in Houston (2012-2017).

Al-Obaidi M, Hasbun R, Vigil KJ, Edwards AR, Chavez V, Hall DR, Dar WA, De Golovine A, Ostrosky-Zeichner L, Bynon JS, Nigo M.

Open Forum Infect Dis. 2019 Jul 1;6(7). pii: ofz172. doi: 10.1093/ofid/ofz172.

6.

Extensively Drug-Resistant Pseudomonas aeruginosa ST309 Harboring Tandem Guiana Extended Spectrum β-Lactamase Enzymes: A Newly Emerging Threat in the United States.

Khan A, Tran TT, Rios R, Hanson B, Shropshire WC, Sun Z, Diaz L, Dinh AQ, Wanger A, Ostrosky-Zeichner L, Palzkill T, Arias CA, Miller WR.

Open Forum Infect Dis. 2019 Jun 6;6(7):ofz273. doi: 10.1093/ofid/ofz273. eCollection 2019 Jul.

7.

Azole resistance and cyp51A mutation screening in Aspergillus fumigatus in Mexico.

Gonzalez-Lara MF, Roman-Montes CM, Diaz-Lomeli P, Rangel-Cordero A, Valenzuela MO, Ponce-de-Leon A, Sifuentes-Osornio J, Ostrosky-Zeichner L, Martinez-Gamboa A.

J Antimicrob Chemother. 2019 Jul 1;74(7):2047-2050. doi: 10.1093/jac/dkz121.

PMID:
31220262
8.

Hurricane-Associated Mold Exposures Among Patients at Risk for Invasive Mold Infections After Hurricane Harvey - Houston, Texas, 2017.

Chow NA, Toda M, Pennington AF, Anassi E, Atmar RL, Cox-Ganser JM, Da Silva J, Garcia B, Kontoyiannis DP, Ostrosky-Zeichner L, Leining LM, McCarty J, Al Mohajer M, Murthy BP, Park JH, Schulte J, Shuford JA, Skrobarcek KA, Solomon S, Strysko J, Chiller TM, Jackson BR, Chew GL, Beer KD.

MMWR Morb Mortal Wkly Rep. 2019 May 31;68(21):469-473. doi: 10.15585/mmwr.mm6821a1.

9.

Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia.

Isturiz RE, Ramirez J, Self WH, Grijalva CG, Counselman FL, Volturo G, Ostrosky-Zeichner L, Peyrani P, Wunderink RG, Sherwin R, Overcash JS, Oliva SP, File T, Wiemken TL, McLaughlin JM, Pride MW, Gray S, Alexander R, Ford KD, Jiang Q, Jodar L.

Vaccine. 2019 May 31;37(25):3352-3361. doi: 10.1016/j.vaccine.2019.04.087. Epub 2019 May 6.

10.

Changes in Prevalence of Health Care-Associated Infections.

Chaturvedi V, Ostrosky-Zeichner L.

N Engl J Med. 2019 Mar 14;380(11):1085. doi: 10.1056/NEJMc1817140. No abstract available.

PMID:
30865810
11.

Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.

Kullberg BJ, Viscoli C, Pappas PG, Vazquez J, Ostrosky-Zeichner L, Rotstein C, Sobel JD, Herbrecht R, Rahav G, Jaruratanasirikul S, Chetchotisakd P, Van Wijngaerden E, De Waele J, Lademacher C, Engelhardt M, Kovanda L, Croos-Dabrera R, Fredericks C, Thompson GR.

Clin Infect Dis. 2019 May 30;68(12):1981-1989. doi: 10.1093/cid/ciy827.

PMID:
30289478
12.

Post-exposure prophylaxis with isavuconazole after occupational exposure to Rhizopus.

Al-Obaidi M, Younes P, Ostrosky-Zeichner L.

Oxf Med Case Reports. 2018 Sep 18;2018(10):omy062. doi: 10.1093/omcr/omy062. eCollection 2018 Oct.

13.

In Vitro Evaluation of BacT/Alert FA Blood Culture Bottles and T2Candida Assay for Detection of Candida in the Presence of Antifungals.

Beyda ND, Amadio J, Rodriguez JR, Malinowski K, Garey KW, Wanger A, Ostrosky-Zeichner L.

J Clin Microbiol. 2018 Jul 26;56(8). pii: e00471-18. doi: 10.1128/JCM.00471-18. Print 2018 Aug.

14.

A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases.

Revankar SG, Baddley JW, Chen SC, Kauffman CA, Slavin M, Vazquez JA, Seas C, Morris MI, Nguyen MH, Shoham S, Thompson GR 3rd, Alexander BD, Simkins J, Ostrosky-Zeichner L, Mullane K, Alangaden G, Andes DR, Cornely OA, Wahlers K, Lockhart SR, Pappas PG.

Open Forum Infect Dis. 2017 Sep 26;4(4):ofx200. doi: 10.1093/ofid/ofx200. eCollection 2017 Fall.

15.

Invasive candidiasis.

Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ.

Nat Rev Dis Primers. 2018 May 11;4:18026. doi: 10.1038/nrdp.2018.26. Review.

PMID:
29749387
16.

Outpatient Infection Prevention: A Practical Primer.

Steinkuller F, Harris K, Vigil KJ, Ostrosky-Zeichner L.

Open Forum Infect Dis. 2018 May 2;5(5):ofy053. doi: 10.1093/ofid/ofy053. eCollection 2018 May.

17.

Isavuconazole for treatment of rare invasive fungal diseases.

Cornely OA, Mullane KM, Ostrosky-Zeichner L, Maher RM, Croos-Dabrera R, Lu Q, Lademacher C, Perfect JR, Oren I, Schmitt-Hoffmann AH, Giladi M, Marty FM, Rahav G.

Mycoses. 2018 Aug;61(8):518-533. doi: 10.1111/myc.12778.

PMID:
29611246
18.

Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.

Marty FM, Cornely OA, Mullane KM, Ostrosky-Zeichner L, Maher RM, Croos-Dabrera R, Lu Q, Lademacher C, Oren I, Schmitt-Hoffmann AH, Giladi M, Rahav G, Perfect JR.

Mycoses. 2018 Jul;61(7):485-497. doi: 10.1111/myc.12777. Epub 2018 Apr 26.

PMID:
29611227
19.

Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.

Perfect JR, Cornely OA, Heep M, Ostrosky-Zeichner L, Mullane KM, Maher R, Croos-Dabrera R, Lademacher C, Engelhardt M, Chen C, Marty FM.

Mycoses. 2018 Jul;61(7):420-429. doi: 10.1111/myc.12769. Epub 2018 Apr 19. Review.

20.

Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel.

Clancy CJ, Pappas PG, Vazquez J, Judson MA, Kontoyiannis DP, Thompson GR 3rd, Garey KW, Reboli A, Greenberg RN, Apewokin S, Lyon GM 3rd, Ostrosky-Zeichner L, Wu AHB, Tobin E, Nguyen MH, Caliendo AM.

Clin Infect Dis. 2018 May 17;66(11):1678-1686. doi: 10.1093/cid/cix1095.

PMID:
29438475
21.

Clinical Outcomes in Patients With Gram-Negative Infections Treated With Optimized Dosing Cefepime Over Various Minimum Inhibitory Concentrations.

Altshuler J, Guervil DJ, Ericsson CD, Wanger A, Aitken SL, Ostrosky-Zeichner L.

J Pharm Pract. 2018 Feb;31(1):34-39. doi: 10.1177/0897190017696950. Epub 2017 Mar 6.

PMID:
29278990
22.

Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on Candida bloodstream infection mortality, a retrospective analysis.

González-Lara MF, Torres-González P, Cornejo-Juárez P, Velázquez-Acosta C, Martinez-Gamboa A, Rangel-Cordero A, Bobadilla-Del-Valle M, Ostrosky-Zeichner L, Ponce-de-León A, Sifuentes-Osornio J.

BMC Infect Dis. 2017 Dec 6;17(1):753. doi: 10.1186/s12879-017-2846-2.

23.

Outbreak Response and Incident Management: SHEA Guidance and Resources for Healthcare Epidemiologists in United States Acute-Care Hospitals.

Banach DB, Johnston BL, Al-Zubeidi D, Bartlett AH, Bleasdale SC, Deloney VM, Enfield KB, Guzman-Cottrill JA, Lowe C, Ostrosky-Zeichner L, Popovich KJ, Patel PK, Ravin K, Rowe T, Shenoy ES, Stienecker R, Tosh PK, Trivedi KK; Outbreak Response Training Program (ORTP) Advisory Panel.

Infect Control Hosp Epidemiol. 2017 Dec;38(12):1393-1419. doi: 10.1017/ice.2017.212. Epub 2017 Nov 30. No abstract available.

PMID:
29187263
24.

The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus.

Ostrosky-Zeichner L, Andes D.

J Infect Dis. 2017 Aug 15;216(suppl_3):S452-S457. doi: 10.1093/infdis/jix239.

PMID:
28911047
25.

Thinking beyond the Common Candida Species: Need for Species-Level Identification of Candida Due to the Emergence of Multidrug-Resistant Candida auris.

Lockhart SR, Jackson BR, Vallabhaneni S, Ostrosky-Zeichner L, Pappas PG, Chiller T.

J Clin Microbiol. 2017 Dec;55(12):3324-3327. doi: 10.1128/JCM.01355-17. Epub 2017 Sep 13.

26.

Drugs in Clinical Development for Fungal Infections.

Gonzalez-Lara MF, Sifuentes-Osornio J, Ostrosky-Zeichner L.

Drugs. 2017 Sep;77(14):1505-1518. doi: 10.1007/s40265-017-0805-2. Review.

PMID:
28840541
27.

Progressive Dispersion of Azole Resistance in Aspergillus fumigatus: Fatal Invasive Aspergillosis in a Patient with Acute Myeloid Leukemia Infected with an A. fumigatus Strain with a cyp51A TR46 Y121F M172I T289A Allele.

Rößler S, Bader O, Stölzel F, Sommer U, Spiess B, Geibel S, Buchheidt D, Groß U, Baretton G, Jacobs E, Ostrosky-Zeichner L.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00270-17. doi: 10.1128/AAC.00270-17. Print 2017 Aug.

28.

Invasive Fungal Infections in the Intensive Care Unit.

Ostrosky-Zeichner L, Al-Obaidi M.

Infect Dis Clin North Am. 2017 Sep;31(3):475-487. doi: 10.1016/j.idc.2017.05.005. Epub 2017 Jul 5. Review.

PMID:
28687215
29.

A Risk Score for Fluconazole Failure among Patients with Candidemia.

Ostrosky-Zeichner L, Harrington R, Azie N, Yang H, Li N, Zhao J, Koo V, Wu EQ.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02091-16. doi: 10.1128/AAC.02091-16. Print 2017 May.

30.

Intensive care medicine research agenda on invasive fungal infection in critically ill patients.

Bassetti M, Garnacho-Montero J, Calandra T, Kullberg B, Dimopoulos G, Azoulay E, Chakrabarti A, Kett D, Leon C, Ostrosky-Zeichner L, Sanguinetti M, Timsit JF, Richardson MD, Shorr A, Cornely OA.

Intensive Care Med. 2017 Sep;43(9):1225-1238. doi: 10.1007/s00134-017-4731-2. Epub 2017 Mar 2. Review.

PMID:
28255613
31.

40 years of medical mycology at JAC.

Ostrosky-Zeichner L.

J Antimicrob Chemother. 2016 Dec;71(12):3327-3329. Review.

PMID:
27856701
32.

Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12).

Chiotos K, Vendetti N, Zaoutis TE, Baddley J, Ostrosky-Zeichner L, Pappas P, Fisher BT.

J Antimicrob Chemother. 2016 Dec;71(12):3536-3539. Epub 2016 Jul 27.

33.

Clinical Characteristics and Predictors of Adverse Outcome in Adult and Pediatric Patients With Healthcare-Associated Ventriculitis and Meningitis.

Srihawan C, Castelblanco RL, Salazar L, Wootton SH, Aguilera E, Ostrosky-Zeichner L, Sandberg DI, Choi HA, Lee K, Kitigawa R, Tandon N, Hasbun R.

Open Forum Infect Dis. 2016 Apr 13;3(2):ofw077. doi: 10.1093/ofid/ofw077. eCollection 2016 Apr.

34.

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

Thompson GR 3rd, Rendon A, Ribeiro Dos Santos R, Queiroz-Telles F, Ostrosky-Zeichner L, Azie N, Maher R, Lee M, Kovanda L, Engelhardt M, Vazquez JA, Cornely OA, Perfect JR.

Clin Infect Dis. 2016 Aug 1;63(3):356-62. doi: 10.1093/cid/ciw305. Epub 2016 May 11.

35.

Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.

Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Ráčil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JH, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJGT; VITAL and FungiScope Mucormycosis Investigators.

Lancet Infect Dis. 2016 Jul;16(7):828-837. doi: 10.1016/S1473-3099(16)00071-2. Epub 2016 Mar 9.

PMID:
26969258
36.

Fungal Infections.

Ostrosky-Zeichner L, Sobel JD.

Infect Dis Clin North Am. 2016 Mar;30(1):xiii-xiv. doi: 10.1016/j.idc.2015.12.001. No abstract available.

PMID:
26897069
37.

Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD.

Clin Infect Dis. 2016 Feb 15;62(4):409-17. doi: 10.1093/cid/civ1194. Review.

PMID:
26810419
38.

Multilaboratory Evaluation of In Vitro Antifungal Susceptibility Testing of Dermatophytes for ME1111.

Ghannoum M, Chaturvedi V, Diekema D, Ostrosky-Zeichner L, Rennie R, Walsh T, Wengenack N, Fothergill A, Wiederhold N.

J Clin Microbiol. 2016 Mar;54(3):662-5. doi: 10.1128/JCM.03019-15. Epub 2015 Dec 30.

39.

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD.

Clin Infect Dis. 2016 Feb 15;62(4):e1-50. doi: 10.1093/cid/civ933. Epub 2015 Dec 16.

40.

A pseudo-outbreak of disseminated cryptococcal disease after orthotopic heart transplantation.

Kennedy E, Vanichanan J, Rajapreyar I, Gonzalez B, Nathan S, Gregoric I, Kar B, Loyalka P, Weeks P, Chavez V, Wanger A, Ostrosky Zeichner L.

Mycoses. 2016 Feb;59(2):75-9. doi: 10.1111/myc.12433. Epub 2015 Dec 2.

PMID:
26627342
41.

Cerebrospinal fluid Coccidioides antigen testing in the diagnosis and management of central nervous system coccidioidomycosis.

Bamberger DM, Pepito BS, Proia LA, Ostrosky-Zeichner L, Ashraf M, Marty F, Scully E, Wheat LJ.

Mycoses. 2015 Oct;58(10):598-602. doi: 10.1111/myc.12366. Epub 2015 Sep 3.

PMID:
26393436
42.

Reply to Bauer and Goff.

Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM, Kontoyiannis DP, Pappas PG.

Clin Infect Dis. 2015 Aug 1;61(3):487-8. doi: 10.1093/cid/civ357. Epub 2015 May 5. No abstract available.

PMID:
25944341
43.

Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia.

Aitken SL, Altshuler J, Guervil DJ, Hirsch EB, Ostrosky-Zeichner LL, Ericsson CD, Tam VH.

Int J Antimicrob Agents. 2015 May;45(5):541-4. doi: 10.1016/j.ijantimicag.2014.12.018. Epub 2015 Jan 19.

PMID:
25665726
44.

T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial.

Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM, Kontoyiannis DP, Pappas PG.

Clin Infect Dis. 2015 Mar 15;60(6):892-9. doi: 10.1093/cid/ciu959. Epub 2015 Jan 12.

PMID:
25586686
45.

Tigecycline : a critical safety review.

Kaewpoowat Q, Ostrosky-Zeichner L.

Expert Opin Drug Saf. 2015 Feb;14(2):335-42. doi: 10.1517/14740338.2015.997206. Epub 2014 Dec 25. Review.

PMID:
25539800
46.

Surveillance of Candida spp bloodstream infections: epidemiological trends and risk factors of death in two Mexican tertiary care hospitals.

Corzo-Leon DE, Alvarado-Matute T, Colombo AL, Cornejo-Juarez P, Cortes J, Echevarria JI, Guzman-Blanco M, Macias AE, Nucci M, Ostrosky-Zeichner L, Ponce-de-Leon A, Queiroz-Telles F, Santolaya ME, Thompson-Moya L, Tiraboschi IN, Zurita J, Sifuentes-Osornio J.

PLoS One. 2014 May 15;9(5):e97325. doi: 10.1371/journal.pone.0097325. eCollection 2014.

47.

What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients.

León C, Ostrosky-Zeichner L, Schuster M.

Intensive Care Med. 2014 Jun;40(6):808-19. doi: 10.1007/s00134-014-3281-0. Epub 2014 Apr 10. Review.

PMID:
24718642
48.

MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting.

Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron MA, Schuster M, Judson MA, Revankar SG, Caeiro JP, Mangino JE, Mushatt D, Bedimo R, Freifeld A, Nguyen MH, Kauffman CA, Dismukes WE, Westfall AO, Deerman JB, Wood C, Sobel JD, Pappas PG.

Clin Infect Dis. 2014 May;58(9):1219-26. doi: 10.1093/cid/ciu074. Epub 2014 Feb 18.

PMID:
24550378
49.

Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.

Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J, Gonzalez GM, Lass-Flörl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Szeszs MW, St-Germain G, Bonfietti LX, Guarro J, Turnidge J.

Antimicrob Agents Chemother. 2014;58(4):2006-12. doi: 10.1128/AAC.02615-13. Epub 2014 Jan 13.

50.

Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method.

Pfaller MA, Espinel-Ingroff A, Bustamante B, Canton E, Diekema DJ, Fothergill A, Fuller J, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Ostrosky-Zeichner L, Pelaez T, St-Germain G, Turnidge J.

Antimicrob Agents Chemother. 2014;58(2):916-22. doi: 10.1128/AAC.02020-13. Epub 2013 Nov 25.

Supplemental Content

Loading ...
Support Center